rhinosinus
rs
heterogen
group
diseas
signific
increas
health
problem
affect
popul
western
countri
substanti
impact
patient
healthrel
qualiti
life
daili
function
repres
huge
financi
burden
societi
health
care
system
result
direct
indirect
cost
addit
rs
wellunderstood
littl
known
etiolog
pathophysiolog
past
decad
mani
paper
publish
chang
understand
rs
rs
commonli
classifi
acut
chronic
rs
base
symptom
durat
acut
rs
inflammatori
reaction
initi
viral
infect
character
uncompl
mild
moder
case
therefor
first
line
treatment
case
intranas
steroid
antibiot
sever
complic
case
antibiot
combin
topic
steroid
remain
treatment
choic
hand
chronic
rs
actual
subdivid
two
distinct
entiti
chronic
rhinosinus
without
polyp
grow
evid
indic
entiti
specif
inflammatori
pathway
cytokin
profil
author
review
recent
data
regard
clinic
present
cytokin
profil
tissu
remodel
modal
treatment
form
rs
rhinosinus
larg
heterogen
group
diseas
despit
fact
mani
paper
publish
topic
past
decad
littl
known
etiolog
pathophysiolog
nevertheless
amount
knowledg
avail
worldwid
literatur
chang
understand
entiti
rhinosinus
commonli
classifi
acut
ar
chronic
rhinosinus
cr
base
symptom
durat
ar
inflammatori
reaction
character
uncompl
mild
moder
case
therefor
longer
argument
prescrib
antibiot
first
line
treatment
rather
privileg
antiinflammatori
treatment
intranas
steroid
sever
complic
case
antibiot
combin
topic
steroid
remain
treatment
choic
hand
cr
actual
subdivid
two
distinct
entiti
cr
without
polyp
grow
evid
indic
entiti
specif
inflammatori
pathway
cytokin
profil
paper
review
recent
data
rhinosinus
author
hope
review
help
clinician
gain
better
understand
manag
condit
impair
extraocular
movement
reduc
visual
acuiti
sever
headach
unilater
facial
orbit
pain
frontal
lump
neurolog
sign
deficit
ar
typic
preceed
viral
infect
allerg
reaction
virus
account
least
caus
agent
ar
among
rhinoviru
coronaviru
influenza
respiratori
synciti
viru
parainfluenza
viru
play
major
role
ar
becom
bacteri
infect
case
case
rs
sever
complic
particular
condit
infern
trio
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarhali
infect
must
consid
anaerob
report
case
pathophysiolog
ar
involv
interact
predispos
condit
allerg
rhiniti
septal
deform
immun
defici
environment
factor
viral
infect
consequ
inflammatori
respons
mucos
line
nose
paranas
sinus
tabl
summar
differ
predispos
factor
play
role
develop
ar
inflammatori
process
lead
develop
edema
engorg
fluid
extravas
mucu
product
obstruct
sinu
ostium
ostial
obstruct
imped
normal
ventil
drainag
sinu
decreas
partial
pressur
oxygen
decreas
ciliari
clearanc
stasi
secret
secundari
bacteri
infect
thu
ar
first
regard
infecti
process
initi
viral
infect
consid
cytokin
profil
ar
result
thelper
type
cytokin
polar
associ
high
level
tumor
necrosi
also
releas
proinflammatori
cytokin
interleukin
il
cytokin
consid
potent
chemoattract
agent
neutrophil
figur
schemat
inflammatori
cascad
case
rhinoviru
infect
goal
treatment
ar
allevi
minim
symptom
erad
pathogen
underli
caus
therapi
halt
inflamm
promot
sinu
drainag
interest
point
ar
case
resolv
spontan
within
week
tabl
summar
differ
treatment
option
case
ar
earli
phase
ar
symptomat
treatment
suffici
consist
nasal
douch
decongest
exspector
mucolyt
painkil
moder
ar
monotherapi
intranas
glucosteroid
recommend
glucocorticoid
act
glucocorticoid
receptor
inhibit
transcript
proinflammatori
mediat
upregul
inflammatori
respons
consequ
reduc
mucos
inflamm
edema
cellular
infiltr
nasal
congest
improv
episod
acut
rhinosinusitisi
permeabl
sinu
ostium
thu
facilit
ventil
drainag
sinu
reduc
eosinophilia
also
great
help
case
comorbid
allerg
rhiniti
occur
frequent
young
patient
possibl
predispos
factor
develop
ar
treatment
intranas
steroid
in
proven
safe
welltoler
incid
advers
event
greater
observ
placebo
moder
sever
case
topic
steroid
must
use
associ
broad
spectrum
antibiot
mani
studi
includ
random
placebocontrol
trial
demonstr
clinic
effect
combin
actual
provid
greater
symptomat
improv
antibiot
therapi
alon
shorter
time
recoveri
greater
regress
imag
abnorm
antibiot
chosen
acccord
local
bacteri
resist
pattern
effect
safeti
must
effect
pneumonia
h
influenza
common
bacteria
implic
uncompl
communityacquir
acut
bacteri
rhinosinus
unit
state
first
choic
amoxycillin
also
clear
use
antibiot
warrant
patient
sever
rapidli
worsen
symptom
regardless
durat
ill
referr
ear
nose
throat
specialist
mandatori
case
cr
character
chronic
inflamm
nasal
paranas
sinu
mucosa
cytokin
releas
tissu
remodel
includ
chang
extracellular
matrix
ecm
protein
deposit
tissu
structur
accord
european
posit
paper
rhinosinus
nasal
polyp
document
cr
defin
two
symptom
associ
sign
via
nasal
endoscop
ct
scan
ct
scan
therefor
requir
diagnos
cr
cr
also
defin
persist
symptom
week
without
clinic
improv
despit
attempt
medic
treatment
tabl
list
criteria
defin
cr
accord
european
posit
paper
rhinosinus
nasal
polyp
document
unlik
ar
usual
infecti
cr
consid
inflammatori
condit
base
nasal
endoscopi
cr
subdivid
two
categori
cr
without
nasal
polyp
past
two
entiti
consid
express
one
singl
diseas
nasal
polyposi
consid
end
point
evolut
cr
without
nasal
polyp
nowaday
despit
clinic
similar
grow
evid
entiti
complet
dispar
base
distinct
inflammatori
pathway
cytokin
profil
differ
tissu
remodel
cr
without
polyp
account
approxim
cr
case
tabl
summar
criteria
defin
cr
without
polyp
heterogen
condit
structur
abnorm
host
factor
environment
factor
allerg
factor
virus
bacteria
fungi
biofilm
superantigen
variabl
contribut
diseas
symptomatolog
consist
nasal
congest
anterior
posterior
rhinorrhea
reduct
sens
smell
recurr
upper
respiratori
tract
infect
urti
facial
pain
pressur
andor
full
common
group
contrast
cr
polyp
role
bacteria
fungi
cr
tricki
issu
infect
sinus
simpli
colon
lead
complex
aggress
inflammatori
reaction
bacteri
organ
infect
paranas
sinus
involv
acut
exacerb
cr
bacteria
encount
often
one
infern
trio
bacteria
identifi
coagulaseneg
staphylococci
staphylococcu
aureu
enterobacteriacea
corynebacterium
spp
pseudomona
aeruginosa
less
commonli
gramneg
enter
bacteria
anaerob
also
present
eg
propionobacterium
spp
bacteroid
peptococci
dental
origin
suspect
microaerophilia
streptococci
must
encount
bacteria
usual
present
ar
cr
without
polyp
medic
treatment
usual
effect
explain
bacteriolog
factor
bacteria
prone
resist
commonli
prescrib
antibiot
gramneg
bacteria
methicillinresist
aureu
bacteria
also
form
biofilm
sinonas
mucosa
patient
cr
sequestr
bacteria
within
biofilm
allow
bacteria
resist
antibiot
treatment
persist
lowgrad
infect
within
sinu
mucosa
exact
role
biofilm
pathogenesi
cr
still
unclear
explain
persist
rhinorrhea
crust
despit
vitro
activ
antibiot
local
osteiti
underli
bone
also
play
critic
role
elabor
cr
induc
persist
inflammatori
chang
surround
mucosa
concurr
osteiti
found
patient
cr
use
radiograph
patholog
criteria
respect
although
causal
relationship
osteiti
cr
infer
data
clinic
find
correl
well
previou
evid
bone
involv
cr
found
anim
model
reaffirm
associ
underli
osteiti
pathogenesi
cr
bacteri
colon
enterotoxinproduc
aureu
found
increas
preval
patient
nasal
polyp
contrast
patient
cr
without
polyp
increas
preval
enterotoxinspecif
ige
antibodi
role
fungi
cr
debat
sinc
first
public
ponikau
et
al
advoc
fungi
normal
colon
nose
sinus
could
elicit
inflammatori
respons
character
intens
eosinophil
infiltr
nose
sinus
lead
develop
cr
figur
depict
role
fungi
cr
particular
method
collect
surgic
sampl
specif
method
identif
investig
demonstr
fungal
cultur
nasal
secret
posit
consecut
cr
patient
allerg
mucin
found
consecut
surgic
case
cr
allerg
fungal
sinus
af
diagnos
consecut
surgic
case
cr
base
histopatholog
find
cultur
result
group
also
demonstr
cr
patient
react
certain
fungal
stimuli
produc
significantli
p
major
symptom
follow
congest
obstruct
discharg
anterior
posterior
pain
pressur
disturb
reduct
loss
smell
andor
endoscop
sign
follow
discharg
middl
meatu
middl
meatu
ct
sign
eg
mucos
chang
ostiomeat
complex
andor
sinu
higher
amount
compar
control
cr
patient
enhanc
humor
respons
significantli
elev
igg
level
alternaria
spp
cr
patient
react
independ
igemedi
allergi
evidenc
fact
nonallerg
cr
patient
also
produc
respons
fungal
stimuli
final
demonstr
benefit
treatment
topic
amphotericin
b
administr
nasal
lavag
patient
suffer
cr
theori
discuss
past
decad
mani
intern
congress
meet
roundtabl
unfortun
skeptic
still
exist
result
confirm
studi
particularli
efficaci
amphotericin
b
moreov
adequ
method
identif
fungi
detect
patient
cr
control
final
classic
inspiss
allerg
mucin
grossli
histopatholog
ident
found
patient
af
also
seen
patient
without
presenc
involv
fungi
nevertheless
af
true
univers
recogn
fungal
diseas
even
underli
immun
process
still
discuss
af
defin
cr
accompani
presenc
peanutbutteri
extramucos
sinu
inspiss
call
allerg
mucin
histopatholog
contain
mass
pyknot
eosinophil
eosinophil
concret
charcotleyden
crystal
lysophospholipas
spars
number
fungal
hypha
highlight
fungal
silver
stain
af
case
involv
dematiac
fungi
bipolari
spicifera
curvularia
spp
drechslera
spp
af
noninvas
form
fungal
rhinosinus
repres
allerg
hypersensit
ige
mediat
case
disord
analog
allerg
bronchopulmonari
aspergillosi
af
common
diseas
countri
warm
humid
climat
eg
unit
state
india
rare
europ
besid
entiti
cr
sometim
eosinophil
mucin
rhinosinus
sometim
associ
neutrophil
infiltr
eosinophil
infiltr
seem
frequent
case
cr
nasal
polyp
wherea
neutrophil
infiltr
associ
cr
without
polyp
thu
role
fungi
two
entiti
still
controversi
need
investig
cr
character
chronic
inflamm
releas
proinflammatori
cytokin
subsequ
tissu
remodel
remodel
defin
process
lead
transient
perman
chang
tissu
architectur
involv
breakdown
tissu
structur
basement
membran
interstiti
stroma
well
repair
cr
without
nasal
polyp
character
predomin
neutrophil
inflamm
stroma
lesser
concentr
eosinophil
mucos
line
cr
without
polyp
character
basement
membran
thicken
goblet
cell
hyperplasia
glandular
hyperplasia
limit
subepitheli
edema
promin
subepitheli
fibrosi
pauciti
gland
chronic
monocellular
cell
infiltr
neutrophil
lymphocyt
mast
cell
plasma
cell
mast
cell
lymphocyt
sometim
organ
lymphat
follicl
ecm
play
essenti
role
tissu
integr
matrix
metalloproteinas
mmp
major
proteolyt
enzym
involv
ecm
damag
repair
cr
without
polyp
demonstr
increas
concentr
natur
inhibitor
tcell
immunoglobulin
mucin
ratio
seem
counterbalanc
hand
cr
nasal
polyp
increas
concentr
inhibitor
upregul
could
contribut
develop
pseudocyst
seen
nasal
polyposi
figur
show
inflamm
mediat
tissu
remodel
cr
without
polyp
cytokin
profil
cr
without
polyp
mainli
cytokin
polar
lymphocyt
inflammatori
infiltr
made
mostli
neutrophil
low
percentag
eosinophil
mast
cell
plasma
cell
upregul
fig
role
fungi
chronic
rhinosinus
fungi
elicit
inflammatori
respons
lymphocyt
lymphocyt
trigger
releas
major
basic
protein
mbp
eosinophil
mbp
normal
synthes
destroy
foreign
agent
virus
parasit
case
mbp
caus
ulcer
mucu
membran
nose
sinus
give
rise
bacteri
sinus
adapt
ponikau
et
al
proinflammatori
cytokin
transform
growth
factor
tgf
unlik
nasal
polyposi
forkhead
box
tbox
transcript
factor
tbet
gatabind
protein
significantli
elev
compar
control
also
polymorph
within
il
receptor
antitrypsin
tabl
review
differ
cytokin
adhes
molecul
growth
factor
implic
differ
form
cr
treatment
cr
without
polyp
medic
surgic
first
step
manag
underli
caus
contribut
factor
antibiot
frequent
prescrib
gener
practition
cr
antibiot
clearli
indic
treatment
acut
bacteri
exacerb
cr
amoxicillin
amoxicillin
plu
clavulan
acid
remain
first
choic
use
fluoroquinolon
urti
evok
act
gramneg
bacteria
nevertheless
first
line
treatment
urti
must
keep
mind
cr
complex
multifactori
inflammatori
diseas
rather
sole
infecti
problem
one
clear
indic
prescrib
fluoroquinolon
treat
infect
p
aeruginosa
prolong
use
lowdos
macrolid
propos
due
antiinflammatori
effect
durat
treatment
vari
week
nasal
douch
intranas
salin
shown
decreas
nasal
symptom
chronic
sinus
improv
qualiti
life
among
patient
cr
reduc
amount
secret
postnas
drip
load
mediat
secret
glucocorticoid
administ
topic
intranas
system
foundat
treatment
cr
associ
antibiot
sever
random
doubleblind
studi
shown
glucocorticoid
effect
treatment
cr
without
polyp
howev
studi
demonstr
minor
improv
without
concomit
surgeri
partial
explain
lack
penetr
sinus
topic
appli
drug
cr
eosinophil
inflamm
topic
steroid
routin
prescrib
least
month
report
system
local
advers
event
tabl
review
differ
option
medic
treatment
cr
without
polyp
surgeri
consid
persist
partial
relief
symptomatolog
despit
maxim
medic
treatment
surgeri
may
also
requir
improv
sinu
aerat
nasal
access
topic
therapi
surgeri
function
concept
restor
aerat
drainag
paranas
caviti
preserv
healthi
mucosa
ethmoid
roof
lamina
papyracea
postop
patient
experi
signific
reduct
headach
nasal
obstruct
postnas
drip
improv
qualityoflif
score
patient
asthma
function
endoscop
sinu
surgeri
improv
peak
expiratori
flow
reduc
use
inhal
system
glucocorticosteroid
public
suggest
use
topic
steroid
postop
period
improv
wound
heal
nasal
polyposi
subgroup
cr
remain
one
difficult
challeng
otolaryngolog
etiolog
pathophysiolog
still
unclear
medic
treatment
unsatisfactori
frequent
recurr
repeat
surgic
procedur
often
necessari
nasal
polyp
present
edemat
semitransluc
mass
origin
mucos
line
sinus
prolaps
nasal
caviti
nasal
endoscopi
show
bilater
later
middl
turbin
middl
meatu
frequent
present
superior
meatu
polyposi
unilater
anoth
diagnosi
must
consid
eg
schneiderian
papilloma
tumor
adult
dermoid
cyst
meningoencephalocel
nasal
glioma
children
symptomatolog
similar
cr
without
polyp
tabl
frequent
nasal
congest
anterior
posterior
nasal
discharg
recurr
episod
respiratori
tract
infect
reduct
loss
sens
smell
import
symptom
patient
nasal
polyp
headach
facial
painpressur
less
common
cr
without
polyp
concern
bacteriolog
organ
describ
section
chronic
rhinosinus
without
polyp
infect
nasal
polyposi
infern
trio
associ
recurr
polyposi
acut
bacteri
exacerb
sinus
antibioticresist
organ
biofilm
osteiti
also
associ
polyposi
specif
item
discuss
case
nasal
polyposi
role
bacteri
colon
aureusproduc
enterotoxin
enterotoxin
aureu
act
local
superantigen
lymphocyt
induc
multiclon
bcell
activ
releas
cytokin
cell
result
eosinophil
activ
releas
eosinophil
cation
protein
ecp
ecp
caus
tissu
damag
edema
format
albumin
accumul
bcell
activ
result
product
multiclon
ige
plasma
contrast
patient
cr
without
polyp
evid
increas
preval
enterotoxinspecif
ige
antibodi
figur
show
possibl
role
enterotoxin
produc
aureu
pathophysiolog
nasal
polyp
nasal
polyposi
constitut
heterogen
group
diseas
base
type
inflammatori
infiltr
subdivid
nasal
polyp
two
group
eosinophil
neutrophil
tabl
list
differ
subpopul
nasal
polyp
nasal
polyposi
affect
gener
popul
western
countri
common
atop
individu
healthi
control
interest
note
belgian
popul
sensit
least
one
aeroallergen
nasal
polyposi
associ
nonallerg
asthma
nasal
polyposi
associ
aspirin
sensit
samter
triad
aspirinexacerb
respiratori
diseas
repres
subset
patient
sever
recalcitr
nasal
polyposi
asthma
set
aspirin
sensit
underli
pathophysiolog
appear
dysregul
eicosanoid
metabol
pathway
lead
increas
product
cysteinyl
leukotrien
decreas
level
prostaglandin
churgstrauss
syndrom
allerg
granulomat
angiiti
character
inflamm
small
arteri
vein
individu
histori
asthma
allergi
besid
inflamm
blood
vessel
also
increas
number
eosinophil
inflammatori
nodular
lesion
nasal
polyp
present
patient
af
associ
nasal
polyposi
case
histolog
polyp
cover
respiratori
pseudostratifi
columnar
epithelium
area
squamou
metaplasia
frequent
epitheli
damag
epithelium
shed
variabl
stage
thicken
basement
membran
pseudocyst
format
edema
two
major
characterist
nasal
polyp
pseudocyst
contain
albumin
plasma
protein
number
vessel
gland
reduc
virtual
neuron
structur
fibroblast
infiltr
inflammatori
cell
local
around
pseudocyst
format
activ
eosinophil
usual
locat
around
vessel
gland
predomin
patient
nasal
polyp
number
degranul
epitheli
mast
cell
high
nasal
polyp
ecm
sever
damag
explain
fact
balanc
mmp
tissu
inhibitor
mmp
shown
displac
favour
mmp
especi
also
demonstr
modif
angiogenesi
nasal
polyp
via
vascular
endotheli
growth
factor
vascular
endotheli
growth
factor
play
role
induc
edema
angiogenesi
fibrosi
demonstr
intens
express
nasal
polyp
mainli
inflammatori
cell
also
epitheli
cell
upregul
secret
nasal
polyposi
caucasian
patient
predominantli
eosinophil
inflamm
tabl
associ
high
level
rant
regul
activ
normal
tcell
express
secret
granulocytemacrophag
colonystimul
factor
eotaxin
play
role
recruit
activ
eosinophil
decreas
apoptosi
concentr
ecp
high
upregul
cysteinylleukotrien
synthesi
signific
differ
polyp
found
patient
without
samter
triad
asthma
explain
benefit
observ
treatment
antileukotrien
modifi
nasal
polyposi
decreas
express
accompani
upregul
tbet
gatabind
protein
downregul
treatment
in
express
increas
elev
level
total
specif
ige
polyp
tissu
anoth
major
characterist
nasal
polyposi
concentr
may
high
kul
often
unrel
serum
ige
level
skin
prick
test
posit
contrast
allerg
rhiniti
product
heterogen
bachert
et
al
demonstr
three
differ
categori
patient
nasal
polyposi
group
demonstr
measur
specif
ige
nasal
polyposi
group
select
specif
ige
third
group
demonstr
multiclon
tabl
eosinophil
cation
protein
increas
local
product
multiclon
product
ige
specif
ige
includ
ige
aureu
enterotoxin
high
total
ige
level
high
preval
asthma
latter
group
patient
usual
sensit
aspirin
consid
treatment
interest
note
chines
patient
neutrophil
eosinophil
polyp
polyp
also
seen
inherit
diseas
primari
ciliari
diskinesia
cystic
fibrosi
chines
patient
polyp
character
band
tcell
activ
minor
eosinophil
inflamm
compar
polyp
white
individu
decreas
comparison
control
one
third
patient
polyp
show
ige
respons
aureu
enterotoxin
figur
show
put
mechan
cell
mediat
impli
cr
polyp
chines
polyp
manag
nasal
polyp
extrem
individu
must
discuss
case
case
expect
one
patient
necessari
other
treatment
medic
surgic
goal
treatment
reestablish
nasal
airway
nasal
breath
minim
symptom
improv
sens
smell
treat
coexist
diseas
asthma
improv
qualiti
life
prevent
complic
start
therapi
import
inform
patient
nasal
polyposi
chronic
sinu
diseas
imposs
cure
potenti
stabil
differ
medic
recurr
rule
observ
complianc
treatment
postpon
long
possibl
relaps
diseas
samter
triad
import
avoid
definit
form
acetylsalicyl
acid
nsaid
corticosteroid
firstchoic
treatment
approach
eosinophil
polyposi
suppress
mani
phase
inflammatori
process
exampl
inhibit
liber
vasoact
mediat
reduc
vasodilat
fluid
extravas
edema
local
deposit
mediat
also
reduc
recruit
inflammatori
cell
fibroblast
prolifer
synthesi
extracellular
matrix
protein
system
applic
affect
polyp
tissu
within
nose
sinus
disadvantag
system
advers
effect
use
longterm
treatment
hissaria
et
al
demonstr
random
placebocontrol
trial
efficaci
cours
mg
prednisolon
patient
symptom
qualiti
life
endoscop
score
nevertheless
clinic
point
view
patient
may
experi
rebound
effect
cours
system
corticosteroid
topic
applic
corticosteroid
dramat
reduc
risk
system
side
effect
mani
studi
demonstr
safeti
efficaci
in
nasal
polyposi
even
intrasinu
portion
polyp
reachabl
nasal
spray
among
special
mometason
furoat
fluticason
furoat
newest
safest
molecul
lowest
bioavail
nasal
polyposi
antibiot
full
dose
recommend
treat
acut
bacteri
exacerb
sinus
recent
year
consider
evid
emerg
suggest
macrolid
antibiot
low
dose
could
play
role
treatment
nasal
polyposi
macrolid
immunomodulatori
properti
addit
wellestablish
antimicrobi
activ
inde
macrolid
antibiot
inhibit
synthesi
andor
secret
proinflammatori
cytkin
granulocytemacrophag
colonystimul
factor
tumor
necrosi
factor
mani
effect
neutrophil
decreas
neutrophil
oxid
burst
inhibit
neutrophil
migrat
inflammatori
site
increas
apoptosi
neutrophil
inhibit
neutrophil
adhes
also
decreas
eosinophil
inflamm
reduc
goblet
cell
secret
decreas
bronchoconstrict
studi
confirm
clinic
efficaci
signific
reduct
size
polyp
reduct
symptom
nasal
obstruct
nasal
discharg
purul
headach
relaps
polyp
seem
delay
howev
studi
demonstr
necess
longterm
use
month
slow
onset
week
treatment
patient
indic
improv
week
improv
week
improv
week
improv
consid
longterm
treatment
gastrointestin
intoler
problem
observ
treatment
moreov
low
dose
emerg
antibioticresist
bacteria
taken
consider
antihistamin
typic
one
medic
choic
treat
allerg
rhiniti
despit
sever
theoret
pharmacolog
properti
applic
treatment
nasal
polyposi
consensu
group
newgener
antihistmain
conga
littl
publish
indic
antileukotrien
shown
effect
nasal
polyposi
chang
arachidon
acid
metabol
suggest
involv
pathogenesi
nasal
polyposi
especi
aspirinsensit
individu
cysteinyl
leukotrien
found
increas
level
nasal
tissu
patient
wherea
concentr
prostaglandin
e
decreas
furthermor
leukotrien
c
synthas
found
upregul
patient
nasal
polyp
number
leukocyt
express
cysteinyl
leukotrien
receptor
compar
nonaspirinsensit
counterpart
thu
use
leukotrien
antagonist
especi
aspirinsensit
nasal
polyp
patient
seem
appropri
howev
largescal
control
trial
clearli
character
patientswith
without
aspirin
sensitivityar
lack
thu
far
patient
aspirin
sensit
aspirin
desensit
recommend
aspirin
desensit
consist
administ
increment
oral
dose
reach
mainten
dose
greater
mgd
induc
refractori
period
day
continu
treatment
year
may
lead
signific
reduct
number
sinu
infect
per
year
improv
olfact
reduct
use
system
corticosteroid
treatment
daili
aspirin
may
therapeut
option
patient
respond
topic
system
corticosteroid
new
treatment
option
must
consid
doxycyclin
antiig
doxycyclin
antibiot
also
inhibit
synthesi
mmp
activ
vitro
howev
doxycyclin
affect
inhibitor
tissu
inhibitor
metalloproteinas
doubleblind
placebocontrol
studi
demonstr
patient
signific
decreas
endoscop
nasal
polyp
score
week
start
doxyclin
treatment
compar
placebo
concentr
ige
myelo
fig
put
mechan
cell
mediat
impli
white
patient
chronic
rhinosinus
cr
polyp
polyp
chines
patient
b
treatment
indic
frame
white
patient
nasal
polyposi
thought
orchestr
thelper
type
cell
interleukin
il
major
cytokin
critic
role
activ
eosinophil
product
ige
steroid
antileukotrien
lt
antihistamin
antiig
omalizumab
may
inhibit
polyp
diseas
differ
level
downregul
transform
growth
factor
tgf
observ
asian
white
individu
nasal
polyp
predomin
teffector
cell
asian
patient
cell
secret
result
predomin
neutrophil
inflamm
mediat
tissu
remodel
cr
without
polyp
shown
thought
play
critic
role
develop
cr
without
polyp
stimul
fibroblast
prolifer
collagen
deposit
inhibit
matrix
metalloproteinas
mmp
enhanc
tissu
inhibitor
metalloproteinas
ecpeosinophil
cation
protein
gmcsfgranulocytemacrophag
colonystimul
factor
ifninterferon
mpomyeloperoxidas
peroxidas
ecp
decreas
significantli
nasal
secret
doxycyclinetr
patient
clinic
set
use
doxycyclin
offer
addit
advantag
provid
antimicrobi
antiinflammatori
effect
result
decreas
nasal
polyp
size
increas
polyp
tissu
relat
eosinophil
inflamm
monoclon
antibodi
treatment
vitro
induc
eosinophil
apoptosi
cytokin
reason
target
antibodi
therapi
nasal
polyp
differ
human
monoclon
antibodi
develop
studi
asthma
pilot
studi
nasal
polyposi
provid
promis
result
consid
mark
local
product
ige
antibodi
nasal
polyp
relat
sever
diseas
appear
local
ige
function
involv
regul
chronic
inflamm
thu
strategi
antagon
ige
could
relev
treatment
allerg
asthma
rhiniti
omalizumab
human
antiig
monoclon
antibodi
caus
mark
reduct
circul
free
ige
level
studi
nasal
polyposi
publish
howev
least
two
team
alreadi
thought
possibl
clinic
applic
antiig
sever
nasal
polyposi
regardless
whether
associ
corticodepend
asthma
manag
nasal
polyposi
usual
involv
medic
treatment
frequent
surgeri
adjunct
medic
treatment
surgic
remov
nasal
polyp
indic
patient
respond
adequ
medic
manag
continu
recurr
infect
well
patient
develop
mucocel
complic
sinus
patient
polyp
asthma
may
benefit
surgeri
reduct
one
trigger
asthma
type
surgeri
perform
subject
debat
europ
respect
place
endoscopicguid
polypectomi
versu
function
endoscop
sinu
surgeri
versu
nasal
recommend
dr
jankowski
nanci
function
endoscop
sinu
surgeri
still
gold
standard
must
open
ethmoid
compart
must
clear
frontal
recess
complet
must
larg
sphenoidotomi
case
question
remain
unansw
long
complet
ethmoidectomi
recommend
power
instrument
microdebrid
appear
particularli
help
extens
polyposi
allow
precis
remov
polyp
good
visual
control
preserv
anatomi
minim
mucos
trauma
strip
guarante
minim
crust
format
rapid
mucos
heal
low
incid
synechia
format
revis
surgeri
anatomi
highli
distort
even
huge
polyposi
surgeri
conduct
navig
system
give
surgeon
confid
particularli
frontal
sinu
area
sphenoid
sinu
seem
reduc
rate
complic
endoscop
sinu
surgeri
shown
lead
signific
improv
total
nasal
resist
measur
rhinomanometri
nasal
volum
measur
acoust
rhinometri
ciliari
beat
frequenc
mucociliari
clearanc
measur
saccharin
test
olfact
measur
univers
pennsylvania
smell
identif
test
increas
evid
also
indic
manag
polyposi
benefit
lower
airway
patient
healthrel
qualiti
life
howev
surgeri
complet
final
definit
step
treat
nasal
polyposi
remain
long
know
chronic
inflammatori
diseas
whose
etiolog
pathophysiolog
still
poorli
understood
longterm
treatment
topic
steroid
surgeri
remain
rule
eosinophil
polyp
reduc
incid
polyp
recurr
prolong
symptomfre
time
interv
rhinosinus
repres
larg
heterogen
group
diseas
ar
mainli
inflammatori
disord
initi
viral
infect
in
seem
best
first
option
treatment
mild
moder
case
cr
without
polyp
mainli
neutrophil
inflamm
antibiot
combin
in
first
choic
treatment
function
sinu
surgeri
usual
necessari
improv
patient
cr
polyp
frustrat
diseas
clinician
recurr
rule
asthma
aspirin
intoler
common
comorbid
caucasian
patient
associ
eosinophil
infiltr
fungi
aureu
enterotoxin
could
play
role
pathophysiolog
glucocorticoid
associ
larg
sinu
surgeri
long
time
treatment
new
treatment
option
seem
promis
specif
doxycyclin
antiig
disclosur
potenti
conflict
interest
relev
articl
report
